A Effect of GO on survival stratified by CD33 expression on CD34+ blasts B Effect of GO dose on survival stratified by CD33 expression on CD34+ blasts.

Slides:

Advertisements

Similar presentations

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Advertisements

Results of a Phase 2 Randomised, Open- Label, Study of Lower Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory.

Unit Test Practice Algebra 2 Unit Q1: Solve for y. 4y + 6 = 18 a) c) a) c) b)d) b)d)

Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < (Log-rank) a Months Low gene expression.

FDA ODAC AML in Older Individuals Frederick R. Appelbaum, MD May 5, 2005.

Hosted by Ms. Williams Properties of Quadrilaterals Properties of Parallelograms Properties of Trapezoids Similar Quadrilaterals.

Isotype ControlCD126 NA A B Supplementary Figure 1. CD126 expression on CLL cells. (A) A representative FACS plot of the isotype control and CD126 staining.

Supplementary Figure 1. Outline of the MRC UKALL 2003 trial protocol detailing drugs used and timing schedules for the three regimens. Patients were allocated.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Similar Outcomes With Hemodialysis and Peritoneal.

5x + 7 = 47 X = 8. d = ac - 20 Express in Scientific Notation.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

P Ferguson, R Hills, A Grech, L Kjeldsen, M Dennis, P Vyas, R Clark, N Russell, C Craddock, On behalf of the NCRI AML Working Group. An operational definition.

3-2 Properties of Parallel Lines. 2) Postulate 10: Corresponding Angles Postulate If two parallel lines are cut by a transversal then the pairs of corresponding.

Supplemental Materials: Anti-apoptotic BCL-2 family proteins as 5-Azacytidine sensitizing targets and determinants of response in myeloid malignancies.

Figure S1. A B C Survival probability (%) P = 0.21 P = 0.37 P = 0.12

S4 Fig. REMARK diagram of course selection for analysis of ctDNA pre-treatment and for ctDNA change after the first and second cycle of chemotherapy. Courses.

TUMOR PD-L1 TIL PD-L1 TUMOR & TIL PD-L1 Age Low High P value R Pearson

Ann Intern Med. 2005;143(6): doi: / Figure Legend: Flow of evidence.

Volume 383, Issue 9928, Pages (May 2014)

Figure 1. Total (A) and free (B) T, estradiol (C), and SHBG (D) levels at baseline and during treatment. From: Testosterone Treatment and Sexual Function.

Figure 1. A B C D E F Survival proability (%) Bone marrow blast count

Image 1 Detection of minimal residual disease (MRD) in consecutive bone marrow (BM) samples from a patient with relapse (A) and a patient still in remission.

Table 1 Baseline patient characteristics

Supplementary Figure 1 Shiota et al.

Supplementary Figure 1 CD45 CD14 FSC CD123 HLA-DR CD11c Lineage

Supplementary Figure 2 Supplementary Figure 2. White blood cell differential count White blood cell (WBC) differential counts were analyzed from patients.

Building better therapy for children with acute lymphoblastic leukemia

The importance of randomisation in evaluation of treatments for Acute Myeloid Leukaemia Lessons from the UK NCRI AML16 and LI-1 trials Ian Thomas, Senior.

Covering the Cover Gastroenterology

Figure 2 The association between CD8+ T‑cell density of the tumour

Supplementary figures

Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.

EHA Stockholm 2018 Deepak Mannari.

Impact of Pre-Transplant Minimal Residual Disease in Patients with AML Undergoing Myeloablative Cord Blood Transplantation Filippo Milano, MD, PhD, Brent.

4155 primary hepatocellular carcinoma with known diagnosis month/year

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

A B Yeom Supplementary Fig.2

New ELN Recommendations

Supplementary Figure 1: Forest plot pooling trials of RRT dose

Monosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia Betul.

Efficacy and Durability of Radiofrequency Ablation for Barrett's Esophagus: Systematic Review and Meta-analysis Eric S. Orman, Nan Li, Nicholas J. Shaheen

Laura MacPherson, Mark A. Dawson Cell Stem Cell

Supplemental Figure 1A Pt Pt Pre-treatment

Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation Philippe Armand, Haesook T. Kim, Daniel.

Supplementary Figure 2 Shiota et al.

Refer to word document for this table

Roth et al, Supplementary Figure 1

Volume 9, Issue 4, Pages (April 2008)

Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia George L. Chen, Hong Liu,

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Supplementary Figure 2A

Volume 383, Issue 9928, Pages (May 2014)

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories by Sanam Loghavi, Dawen Sui, Peng Wei, Guillermo Garcia-Manero, Sherry.

Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation Merav Bar, Weigang Tong, Megan Othus,

Volume 371, Issue 9618, Pages (March 2008)

Improved Outcome for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome Scott R. Solomon, Bipin N. Savani, Richard.

Supplemental Figure 1A SMM Patient #1 MP-CTL % CD3+ CD8+ T Cells

A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia by Lili Aslostovar, Allison L. Boyd, Mohammed.

A B C D Supplementary Figure S1 UMSCC1 Plateau: 24 hr Pre-Treatment

Which of the following expressions is the equation of the function {image} {applet}

Treatment versus Transplant for Challenging Hematologic Disorders

Laura MacPherson, Mark A. Dawson Cell Stem Cell

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Forest plot from meta-analysis carried out on four studies including high-dose N-acetylcysteine (NAC) treatment a) assessing the relative risk of chronic.

Should heart transplantation be considered as a treatment option for patients aged 70 years and older? Jeffrey A Morgan, MD, Ranjit John, MD, Donna M.

Kaplan-Meier plot of overall survival from the time of first dose of intrathecal interleukin-2 (IT IL-2) for all patients (A, n=43) and based on the extent.

Somatic mutational rates and survival analysis of IBD-CRC.

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,

A. B. C. D. Above median: Below median:

Presentation transcript:

A Effect of GO on survival stratified by CD33 expression on CD34+ blasts B Effect of GO dose on survival stratified by CD33 expression on CD34+ blasts

C Effect of GO on relapse stratified by CD33 expression on CD34+ blasts D Effect of GO dose on relapse stratified by CD33 expression on CD34+ blasts Supplementary Figure S8 Pre-treatment CD33 expression levels on CD34+blasts and response to GO in AML patients Forest plot analysis showing effect of CD33 expression on survival (A-B) and relapse (C-D). Response to GO in (A,C) non-CBF patients (younger and older) and in (B,D) GO dose randomisation in younger (NCRI-AML17) patients.